Insider Transaction: David Mott Acquired 70,873 Shares of AVEO Pharmaceuticals, Inc. (AVEO); Profile of 1 Analysts Covering WPT Industrial Real Estate Investment Trust (TSE:WIR.U)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Logo

WPT Industrial Real Estate Investment Trust (TSE:WIR.U) Ratings Coverage

Among 2 analysts covering WPT Industrial REIT (TSE:WIR.U), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. WPT Industrial REIT had 8 analyst reports since August 13, 2015 according to SRatingsIntel. BMO Capital Markets maintained WPT Industrial Real Estate Investment Trust (TSE:WIR.U) on Thursday, March 23 with “Outperform” rating. The stock has “Sector Perform” rating by Scotia Capital on Thursday, August 11. The firm has “Sector Perform” rating given on Wednesday, July 20 by Scotia Capital. The stock has “Sector Perform” rating by Scotia Capital on Thursday, March 16. The firm has “Outperform” rating by Scotia Capital given on Thursday, August 13. See WPT Industrial Real Estate Investment Trust (TSE:WIR.U) latest ratings:

17/11/2017 Broker: Scotia Capital Rating: Sector Perform Old Target: $13.25 New Target: $13.50 Target Up

The stock increased 1.16% or $0.16 during the last trading session, reaching $13.93. About 67,347 shares traded or 24.61% up from the average. WPT Industrial Real Estate Investment Trust (TSE:WIR.U) has 0.00% since May 11, 2017 and is . It has underperformed by 11.55% the S&P500.

WPT Industrial Real Estate Investment Trust is an unincorporated, open-ended real estate investment trust established pursuant to a declaration of trust under the laws of the Province of Ontario. The company has market cap of $670.84 million. The REIT was formed for the purpose of acquiring and owning primarily industrial investment properties located in the United States, with a particular focus on warehouse and distribution industrial real estate. It has a 12 P/E ratio.

Investors sentiment increased to 2.81 in 2017 Q4. Its up 1.49, from 1.32 in 2017Q3. It improved, as 4 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 26 funds opened positions while 19 raised stakes. 59.55 million shares or 0.59% less from 59.90 million shares in 2017Q3 were reported. Venbio Select Advisor Ltd Liability holds 0.72% or 4.01M shares. Excalibur invested in 0.03% or 11,000 shares. Goldman Sachs Grp Inc Inc holds 240,935 shares. Deer Vi And Ltd Limited Liability Company holds 675,242 shares or 100% of its portfolio. Citadel Advisors Ltd Liability Co holds 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) or 843,820 shares. Ra Capital Limited Liability Corporation has invested 1.18% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Edge Wealth Mgmt Limited Liability Corp reported 10,000 shares or 0.01% of all its holdings. Jpmorgan Chase & Company accumulated 0% or 534,533 shares. Armistice Cap Limited Liability invested in 600,000 shares or 0.17% of the stock. Vanguard Grp Incorporated owns 4.36M shares. 28,629 were reported by Schwab Charles Invest Mgmt Inc. Perceptive Ltd Llc reported 2.96M shares. Moreover, Bridgeway Capital has 0.01% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 346,464 shares. Citigroup holds 0% or 2,679 shares in its portfolio. Northern reported 206,033 shares.

More recent AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news were published by: which released: “Here’s Why AVEO Pharmaceuticals Fell as Much as 17% Today” on May 08, 2018. Also published the news titled: “3 Things In Biotech, May 9: New AML Therapy Imminent? AVEO Hedges, Rockwell Boosts Iron” on May 10, 2018.‘s news article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within FNB, Comcast, IZEA, AVEO Pharmaceuticals ..” with publication date: May 09, 2018 was also an interesting one.

The stock decreased 4.93% or $0.12 during the last trading session, reaching $2.22. About 1.36M shares traded. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has risen 351.31% since May 11, 2017 and is uptrending. It has outperformed by 339.76% the S&P500.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $342.22 million. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

David Mott, the major shareholder of Aveo Pharmaceuticals Inc made an unexpected purchase of 70,873 shares with an average price-per-share of $2.1 in the Pinksheet-listed company, that are with a grand total value of $151,250 U.S Dollars . It seems he is very active lately as in the last 30 days, he silently bought additional 920,976 shares of the company, worth $2.12 million USD. Due to the significance of this acquisition, it will not go unseen. David Mott owns 11.26% of the -company’s market cap with a total of 17.35 million shares.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart